72420-38-3

Basic information

• Product Name: ACIFRAN
• Synonyms: ay25712;ACIFRAN;4,5-DIHYDRO-5-METHYL-4-OXO-5-PHENYL-2-FURANCARBOXYLIC ACID;(R,S)-4,5-Dihydro-5-methyl-4-oxo-5-phenyl-2-furancarboxylic acid;4,5-Dihydro-5-methyl-4-oxo-5-phenylfuran-2-carboxylic acid;Acifranum;4,5-dihydro-5-methyl-4-oxo-5-phenyl-2-furancarboxylicaci;5-Methyl-4-oxo-5-phenyl-4,5-dihydro-furan-2-carboxylic acid
• CAS NO: 72420-38-3
• Molecular Formula: C₁₂H₁₀O₄
• Molecular Weight: 218.21
• Product Categories: Miscellaneous Compounds
• Mol File: 72420-38-3.mol
• Article Data: 4

Chemical Properties

• Melting Point: 176°
• Boiling Point: 378.4 °C at 760 mmHg
• Flash Point: 149.4 °C
• Appearance: /
• Density: 1.343 g/cm³
• Vapor Pressure: 2.12E-06mmHg at 25°C
• Refractive Index: 1.591
• Storage Temp.: Store at +4°C
• PKA: 2.25±0.40(Predicted)
• CAS DataBase Reference: ACIFRAN(CAS DataBase Reference)
• NIST Chemistry Reference: ACIFRAN(72420-38-3)
• EPA Substance Registry System: ACIFRAN(72420-38-3)

Safety Data

• Hazardous Substances Data: 72420-38-3(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 72420-38-3 differently. You can refer to the following data:
1. Antihyperlipopro-teinemic.
2. Acifran is a nicotinic acid receptor agonist.

Brand name

Reductol (Wyeth-Ayerst).

Biological Activity

Hypolipidaemic agent; more potent than nicotinic acid and clofibrate. Full and potent agonist at the human orphan GPCR HM74A/GPR109A and GPR109B (EC 50 values are 1.3? and 4.2 μ M respectively). In vivo, reduces serum triglycerides and circulating LDL-cholesterol without affecting liver weight or liver enzymes.

InChI:InChI=1/C12H10O4/c1-12(8-5-3-2-4-6-8)10(13)7-9(16-12)11(14)15/h2-7H,1H3,(H,14,15)

Upstream product

• 3155-01-9 3-hydroxy-3-phenyl-butan-2-one 
• 95-92-1 oxalic acid diethyl ester 
• 72420-48-5 6-methyl-6-phenyltetrahydropyran-2,3,5-trione 
• 618-36-0 rac-methylbenzylamine 
• 78349-04-9 1-(2-methyl-1,3-dithian-2-yl)-1-phenylethan-1-ol 
• 98-86-2 acetophenone 
• 127-66-2 2-Phenyl-3-butyn-2-ol 
• 72429-82-4 methyl 4,5-dihydro-5-methyl-4-oxo-5-phenyl-2-furancarboxylate 

Downstream Products

• 1281970-93-1 N-(2-(2-(2-(5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenamidoethyl)disulfanyl)ethyl)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxamide 
• 1281971-04-7 N-(2-aminoethyl)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxamide hydrochloride 
• 1281970-90-8 N-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamidoethyl)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxamide 
• 1281971-05-8 tert-butyl 2-(2-(2-methyl-3-oxo-2-phenyl-2,3-dihydrofuran-5-carboxamido)ethoxy)ethylcarbamate 
• 1281971-03-6 tert-butyl 2-(2-methyl-3-oxo-2-phenyl-2,3-dihydrofuran-5-carboxamido)ethylcarbamate 
• 72429-82-4 methyl 4,5-dihydro-5-methyl-4-oxo-5-phenyl-2-furancarboxylate 
• 72420-44-1 5-methyl-4-oxo-5-phenyl-4,5-dihydro-furan-2-carboxylic acid pyridin-3-ylmethyl ester 

Relevant articles and documents

Analogues of Acifran: Agonists of the high and low affinity niacin receptors, GPR109a and GPR109b

Recently identified GPCRs, GPR109a and GPR109b, the high and low affinity receptors for niacin, may represent good targets for the development of HDL elevating drugs for the treatment of atherosclerosis. Acifran, an agonist of both receptors, has been tested in human subjects, yet until recently very few analogs had been reported. We describe a series of acifran analogs prepared using newly developed synthetic pathways and evaluated as agonists for GPR109a and GPR109b, resulting in identification of compounds with improved activity at these receptors.

Hypolipidemic derivatives of 4,5-dihydro-4-oxofuran-2-carboxylic acid

Derivatives of 4,5-dihydro-4-oxofuran-2-carboxylic acid characterized by having two substituents at position 5 and in addition being optionally further substituted at position 3 with a lower alkyl group, as well as esters therefor are disclosed. The foreg